clofazimine has been researched along with Long QT Syndrome in 4 studies
Clofazimine: A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619)
clofazimine : 3-Isopropylimino-3,5-dihydro-phenazine in which the hydrogen at position 5 is substituted substituted by a 4-chlorophenyl group, and that at position 2 is substituted by a (4-chlorophenyl)amino group. A dark red crystalline solid, clofazimine is an antimycobacterial and is one of the main drugs used for the treatment of multi-bacillary leprosy. However, it can cause red/brown discolouration of the skin, so other treatments are often preferred in light-skinned patients.
Long QT Syndrome: A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Clofazimine is classified as a WHO group B drug for the treatment of rifampin-resistant tuberculosis." | 9.41 | Effect of Clofazimine Concentration on QT Prolongation in Patients Treated for Tuberculosis. ( Abdelwahab, MT; Court, R; Dawson, R; Denti, P; Diacon, AH; Everitt, D; Maartens, G; Svensson, EM, 2021) |
| "Clofazimine is classified as a WHO group B drug for the treatment of rifampin-resistant tuberculosis." | 5.41 | Effect of Clofazimine Concentration on QT Prolongation in Patients Treated for Tuberculosis. ( Abdelwahab, MT; Court, R; Dawson, R; Denti, P; Diacon, AH; Everitt, D; Maartens, G; Svensson, EM, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, F | 1 |
| Gao, J | 1 |
| Gao, M | 1 |
| Liu, Y | 1 |
| Shu, W | 1 |
| Xie, L | 1 |
| Sun, Y | 1 |
| Zhang, L | 1 |
| Li, L | 1 |
| Pang, Y | 1 |
| Abdelwahab, MT | 1 |
| Court, R | 1 |
| Everitt, D | 1 |
| Diacon, AH | 1 |
| Dawson, R | 1 |
| Svensson, EM | 1 |
| Maartens, G | 1 |
| Denti, P | 1 |
| Ardhianto, D | 1 |
| Fatmawati, U | 1 |
| Zweijpfenning, SMH | 1 |
| van Groningen, H | 1 |
| van Ingen, J | 1 |
| Magis-Escurra, C | 1 |
| Boeree, MJ | 1 |
| Wagner, D | 1 |
| Bax, H | 1 |
| Andrejak, C | 1 |
| Wener, R | 1 |
| Rahman, A | 1 |
| Kunst, H | 1 |
| Lorent, N | 1 |
| Brouwer, MA | 1 |
| Hoefsloot, W | 1 |
1 trial available for clofazimine and Long QT Syndrome
| Article | Year |
|---|---|
Effect of Clofazimine Concentration on QT Prolongation in Patients Treated for Tuberculosis.
Topics: Adult; Clofazimine; Electrocardiography; Heart Rate; Humans; Long QT Syndrome; South Africa; Tubercu | 2021 |
3 other studies available for clofazimine and Long QT Syndrome
| Article | Year |
|---|---|
Development and Validation of a Nomogram for Prediction of QT Interval Prolongation in Patients Administered Bedaquiline-Containing Regimens in China: a Modeling Study.
Topics: Antitubercular Agents; Clofazimine; Creatinine; Diarylquinolines; Humans; Levofloxacin; Long QT Synd | 2022 |
Analysis of the side effect of QTc interval prolongation in the bedaquiline regimen in drug resistant tuberculosis patients.
Topics: Antitubercular Agents; Clofazimine; Diarylquinolines; Drug-Related Side Effects and Adverse Reaction | 2021 |
Clofazimine does not lead to significant QT interval prolongation: a multicentre study.
Topics: Arrhythmias, Cardiac; Clofazimine; Diarylquinolines; Heart; Humans; Long QT Syndrome | 2018 |